Skip to content
NeuroTechGuide

OnVagus wins approval for first human trial of a skin-surface vagus nerve block for cancer wasting

A 10-patient safety study at MD Anderson will test the noninvasive device in people with pancreatic cancer and cachexia.

In briefNeuromodulationClinical trials

OnVagus, a start-up incubated at the Terasaki Institute for Biomedical Innovation in Los Angeles, announced on October 7 that it has institutional and regulatory approval for its first human trial. Its device sits on the skin over the right vagus nerve and delivers low-frequency stimulation to block the nerve’s signals. The eight-week safety study will enroll 10 people with pancreatic cancer and cachexia at MD Anderson Cancer Center, with the first patient expected in October. If results are good, a 120-patient randomized, sham-controlled trial would follow.

Cachexia, a severe loss of weight and muscle, has no FDA-approved treatment. The approach builds on a 2025 Cell study in mice, so whether it helps people is still unknown.

Learn more: Neurotechnology

Share:XLinkedInBlueskyEmail

More news